Format

Send to

Choose Destination
Biochem Biophys Res Commun. 2005 Jul 8;332(3):873-9.

Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations.

Author information

1
Westmead Institute for Cancer Research, University of Sydney, Westmead Millennium Institute, Westmead, NSW 2145, Australia. therese_becker@wmi.usyd.edu.au

Abstract

The cyclin-dependent kinase inhibitor p16INK4a has been identified as tumor suppressor and melanoma predisposition gene. While its cell cycle inhibitory ability is important in protecting cells from uncontrolled growth and possible tumor formation, other functions of p16INK4a are likely to contribute to its nature as a tumor suppressor. p16INK4a binding and inhibition of the transcription factor NF-kappaB has been shown and is consistent with the reports of abnormally increased NF-kappaB activity in various cancers including melanoma. Here, we present evidence that wild type p16INK4a binds to the NF-kappaB subunit RelA more efficiently than melanoma-associated p16INK4a mutations. Furthermore, whereas wild type p16INK4a strongly inhibits NF-kappaB transcriptional activity, a subset of melanoma-associated p16INK4a mutants show reduced NF-kappaB inhibitory function. p16INK4a does not affect NF-kappaB nuclear translocation or DNA binding, suggesting a mechanism that reduces NF-kappaB transactivation activity.

PMID:
15913553
DOI:
10.1016/j.bbrc.2005.05.032
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center